biote Corp (BTMD)
🔔 Watch stock
Basics
Performance
Valuation
Profitability
Balance Sheet & Safety
Growth
Quality & Screener
AI Rating
–Not yet rated — we only show a category once an SEC-backed file with at least two cited passages is available. How the Rating Is Built
Highlighted are things our editorial team noticed: green = stands out as strong, red = deserves a closer look. No single metric is a verdict on its own — always read it in context.
Quarterly Figures
| Quarter | EPS (Earnings Per Share) | EPS YoY (%) | Sales ($M) | Sales YoY (%) | Net Margin (%) | OCF ($M) | FCF ($M) |
|---|---|---|---|---|---|---|---|
| 2024: Q4 | 0.12 | -52.10 | 50 | 9.00 | 7.40 | 12 | 11 |
| 2025: Q1 | 0.45 | – | 49 | 4.70 | 28.00 | 7 | 5 |
| 2025: Q2 | 0.11 | – | 49 | -0.60 | 6.50 | 7 | 5 |
| 2025: Q3 | 0.27 | -23.50 | 48 | -6.70 | 17.10 | 14 | 13 |
| 2025: Q4 | 0.06 | -47.20 | 46 | -6.90 | 4.20 | 8 | 7 |
| 2026: Q1 | 0.08 | -83.40 | 45 | -8.30 | 5.10 | 4 | 3 |
- EPS (Earnings Per Share):
- Quarterly profit divided by the total share count — how much of the profit works out to a single share.
- YoY (Year over Year):
- Change versus the same quarter a year ago — this is how you compare without seasonal distortion (e.g. the holiday shopping season).
- Sales:
- All revenue for the quarter, before any costs are deducted — the top line of the income statement.
- Net Margin:
- What percentage of sales is left over as profit in the end. Negative means the company is posting a loss.
- OCF (Operating Cash Flow):
- The cash that actually flows into the till from the core business during the quarter — harder to dress up than book profit.
- FCF (Free Cash Flow):
- Operating cash flow minus capital expenditures — the money that's genuinely free to use, say for paying down debt, buybacks, or dividends.
About the Company
biote Corp. ist im Bereich Praxisaufbau im Segment der Hormonoptimierung tätig.
| Employees | 223 |
|---|---|
| Headquarters | Irving, TX |
| Website | biote.com |
| IPO Date | 28. Apr 2021 |
| Next Earnings | 5. Aug 2026 |
Management
| Name | Title | Birth Year |
|---|---|---|
| Marc D. Beer | Executive Chairman | 1965 |
| Robert C. Peterson | Interim CEO, CFO, Chief Business Officer & Director | 1977 |
| John J. Olsen | Chief Information Officer | 1957 |
| Dan Monico | General Counsel | – |
| Joel Pickering | Chief Marketing Officer | – |
| Richard Kevin Key | Chief Digital Officer | 1971 |
| Jade Beutler | Head of Nutraceuticals | 1964 |
| Cory Rice D.O. | Chief Clinical Advisor & Member of Medical Advisory Board | – |
| Joey Lopes | SVP of Strategy & Commercial Operations | – |
| Komal Bajaj M.D., M.S. | Chief Medical Officer | – |
Executives per the latest required filings; titles kept in their original language. Source: fundamental data.
Chart
Interactive price chart (TradingView).
Data as of: July 20, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.